Newborns with staphylococcus aureus and coagulase-negative sepsis treated with vancomycin after an increase in serum levels around the valley J Hum Growth Dev. 2018; 28 (1) 
Staphylococcus aureus and coagulase-negative staphylococci are the most common infections in both neonatal and paediatric intensive care units 1, 2 and have a significant impact on patients' mortality and morbidity [3] [4] [5] . Penicillin-resistant staphylococci have emerged since the 1980s, and currently both types are sensitive to vancomycin only. For this reason, this drug has long been considered the gold standard in therapy against these infectious agents 6 . The Food and Drug Administration (FDA) approved vancomycin for use in the United States in 1958 to treat penicillin-resistant1 Staphylococcus aureus infection. It is a complex, glycopeptide antibiotic containing amino acids and sugars and has high molecular 2, 3 weight with activity in the pH range between 6.0 and 8.0. Several situations require the monitoring of serum levels and adjustment of vancomycin doses. Clinical factors such as site and severity of infection, suspected or confirmed infectious agent, underlying disease and concomitant therapies 7 , and the fact that the drug has a narrow therapeutic range all increase the risk of side effects, such as nephritic syndrome and ototoxicity, skin reactions (e.g., erythema), and flushing histamine-like and other anaphylactic reactions, when anaesthetics are given. The association with aminoglycosides and furosemide that is frequent in the sepsis patient increases toxicity. Effects on neuromuscular blockade may be enhanced when nondepolarizing muscle relaxants are administered.
There are important interindividual pharmacokinetic variations (age, weight, renal function) that emphasise the importance of drug monitoring and dosage adjustment in clinical practice 8 . However, even though vancomycin has been used for more than half a century in neonatal care, dosage and efficacy still currently demonstrate its pharmacological complexity.
Preterm infants are susceptible to higher concentrations of free and bioavailable drugs due to: decreased serum protein concentration; high fetal albumin concentration, which has decreased affinity for drug binding; low plasma pH; which reduces protein binding to acidic drugs; and serum concentration of competing molecules at the binding of drugs with proteins, such as bilirubin and free fatty acids. Thus, a standard dose becomes an exaggerated dose and causes toxic effects. On the other hand, the greater volume of drug distribution to tissues leads to a greater need to concentrate drugs per kilo of body weight in order to maintain adequate serum concentration, since protein-free drugs are also more available to be metabolised and excreted 9 . The therapeutic values for use of vancomycin, according to Neofax ® (dosage book used in most Neonatal Units) up to 2009, were 5-10 μg/ml for valley concentrations (4 to 8 times minimum inhibitory concentration (MIC) and 20-40 μg/ml for peak concentrations (10 to 30 MIC) at doses of 10-15 mg/kg 10 . Currently, neonatal referrals recommend higher serum concentrations in the valley of 10-15 μg/ml, but doses remain unchanged 11, 12 . Thus, the objective is to analyse the concentration of serum levels in the voucher (one hour before the next administration of the drug dose) of vancomycin in newborns admitted to a neonatal intensive care unit with Staphylococcus aureus or coagulase-negative oxacillinresistant strains are adequate and according to the literature. This is a retrospective descriptive and interventional study, made when the levels of the drug were outside the range of normal, performed at the Center for Neonatal Intensive Care (CTNI-2) of the Children's Institute of the Hospital das Clínicas of the University of São Paulo, which has 20 beds for newborns hospitalised in serious condition with both clinical and surgical diseases that require specialised care for more than 24 hours.
Voucher is defined as the time period of one hour before the next administration of the dose of the drug. The choice of voucher was given by being routinely dosed to indicate the levels/values of the adequate dosage of the drug in the therapeutic treatment of the newborns until the end of the drug Activity.
Inclusion criteria
We obtained a list of patients who, according to the registry of the unit and the hospital, were admitted to the neonatal ICU of the Children's Institute and had a diagnosis of sepsis by Staphylococcus aureus and/or coagulasenegative. From this list, we randomised newborns (under the age of one year) that were hospitalised between 2001 and 2016 and of life was done. We obtained data collected at the time of administration of vancomycin (i.e., weight, age, gestational age, administered doses of vancomycin, and serum levels) from the medical records of patients with bloodstream infection by Staphylococcus aureus and coagulase-negative using vancomycin as a form of treatment.
level in the vancomycin vial (i.e., above or below the reference value of 10-15 μg/ml), the time interval of drug administration was modified.
The vancomycin voucher as quoted in the introduction is one hour before the next administration of the drug and represents the efficacy thereof, which must still be between the desired values (i.e., it would still be acting even at the end of the time before the next dose.
Data collected from serum levels were statistically analysed using means, medians, standard deviations, and % mean deviation. The present study was approved by the Research and Ethics Committee of the Department of Pediatrics, Faculty of Medicine, University of São Paulo (protocol number: 1.684976).
RESULTS

Exclusion criteria
We excluded patients whose medical records had no serum level registry in the vancomycin voucher or who did not receive it as a form of treatment. All patients who had serum levels in the vancomycin valley below, adequate, or above the reference values were included, even though the admission period of these patients had different serum levels of reference.
The prescription of vancomycin was made according to the literature followed, Neofax ® , which suggests doses according to the weight and gestational age of the newborn. The suggested doses are 10-15 mg/ kg with intervals of administration followed empirically; thus, they could be 6/6 hours, 8/8 hours, 12/12 hours, 18/18 hours, up to 24/24 hours, depending on the serum Table 3 : Serum levels in the vancomycin voucher of the 30 patients studied
DISCUSSION
After 72 hours, the 30 newborns had serum levels in the vancomycin vouchers reassessed. Among them, seven (23.34%) had an adequate serum level, and nine (30%) and 14 (46.67%) had serum levels below and above the literature reference values, respectively. Thus, there was a change in dose and/or dosing interval prescribed for newborns that had lower-and higher-than-expected serum levels, collecting a second serum level after three days. It can be verified that of those who had the first serum level in the appropriate vancomycin valley (23.34%) and below (30%) of the reference, 13.24% of the patients in both cases had a total mean serum level adequately collected with a correct dosage adjustment. However, the 14 patients who had a high score at the first serum level collection in the valley and had their doses of vancomycin modified. It was observed that the mean of all serum levels of 11 of these patients (36.67%) remained high and only three (10%) were adequate.
Only 11 patients (36.67%) had the first serum level in the registered vancomycin voucher. Among them, three (10%) were below the reference values and four (13.34%) were at adequate levels as the same amount of patients with the high levels (Graph 1).
The analysis of the serum levels in the vancomycin valley showed that 60% of the patients were outside the proposed targets, of which 13.64% were below the expected level and 46.36% were above reference values. Serum levels below therapeutic levels are of great concern because there is a delay in the treatment of the infection as well as a greater susceptibility to resistance of the bacteria, forcing the clinician to increase the dosage empirically. Elevated serum levels are also of concern, as they can lead to nephrotoxic and ototoxic problems.
It is noteworthy that the meeting of these increased and low levels, since they are empirically adjusted and for a preterm NB a high dose of Vancomycin can cause renal failure. The waiting procedure for the dose in the valley is adequate and promotes evolution of the infection picture of the newborn.
Another issue of difficult therapeutic management is reaching therapeutic levels in neonates with renal dysfunction, due to the fact that glomerular filtration is responsible for the excretion of vancomycin and also for tubular functions in neonates still immature 13, 14 . Of the 30 newborns, 25% had elevated serum levels and presented renal problems treated with furosemide to improve renal function. In a situation such as this, the half-life of vancomycin may increase from 150-250 hours and provide an increase in the serum concentration of the drug and risk of toxicity, culminating in clinical worsening of the newborn 15 . Dialysis is the gold standard for the reversal of the clinical condition of the newborn and clearance and elimination of vancomycin.
However, in 2007 alone, there were guidelines published through the Infectious Diseases Society of America, along with other professional organisations, with multidisciplinary guidance on this program 16 . However, as far as the neonatal area is concerned, data are lacking on the consequences of these programs 17 .
In the neonatal intensive care unit (ICU), there is routine and frequent use of vancomycin. Sánches et al. 18 point out that vancomycin is used empirically in ICUs, making its use inappropriate. In the 1980s, antimicrobial management programs were introduced with the aim of reducing unnecessary therapies.
It is worth mentioning that the use of vancomycin is very frequent also due to the scarcity of new antibiotics Pharmaceutical industries choose not to invest in the development of new antibiotics because their effectiveness only lasts for around two years due to indiscriminate use by the general population and by health professionals. Since vancomycin has been in use for more than 50 years, it must be used correctly and carefully.
Although there are modifications in the structure of vancomycin, from the introduction of quaternary ammonium salt at the C-terminal generating a second mechanism of action, resulting in better permeability of the drug in the cell wall, as well as being complementary in the inhibition of glycopeptide synthesis of the wall bacterial cell growth, with improvement in its therapeutic effects and reduction of the bacterial resistance event 20 , the valley dosage seems to be more adequate for the clinical conduction of the newborns, especially to avoid the toxicity produced by the drug.
In addition, vancomycin is a glycopeptide antibiotic used to treat infections caused by grampositive micro-organisms. In monitoring the dosages of vancomycin, it is possible to obtain adequate and efficient serum concentrations for the treatment of infections. It is noteworthy that there is controversy in the therapeutic management of newborns with gram-positive micro-organisms, especially in the determination and interpretation of their serum concentrations. Measurement of serum vancomycin levels (vancocinemia) may aid in the prevention of toxicity and in the adequate maintenance of therapeutic serum concentration, avoiding low tissue penetration and failure to eliminate the outbreak of infection.
Monitoring is based on the fact that the therapeutic response depends on the concentration of the drug in the patient's bloodstream and not on the dose administered. The use of regular doses at periodic intervals does not mean constant levels in all patients due to differences in absorption, metabolism, excretion, and bioavailability of the drug administered that influence the definitive therapeutic effect. Thus, the monitoring of serum concentrations both in the peak and in the vancomycin voucher is essential to assess the toxicity or suitability of the medicine used in the clinic of the critically ill neonate.
In the majority of neonates hospitalised in the Unit of Neonatal Intensive Care of the Reference Hospital of Latin America, there was a rate of serum level in the valley raised to the expected standards, causing greater toxic injury. It is clear that the metabolism of each drug depends on the stage of disease in the patient; however, with vancomycin, it is very difficult because the concentration of the drug in the body exceeds the therapeutic range, reaching the toxic dose and often worsening the condition of the newborn. Furthermore, vancomycin is widely used in neonatal intensive care patients who are afflicted with Staphylococcus aureus and coagulase-negative.
The mean values observed in graph 1 show that of the 30 patients analysed, 12 (40%) had adequate serum levels in the valley between the red and green lines (10-15 μg/mL). In four newborns (13.4%), the mean level was below the expected level (below the red line, <10 μg/mL), and 14 newborns had aboveadequate serum levels (above the green line, >15 μg/ mL).
The monitoring of serum levels in the vancomycin valley is of great importance and should be performed in all hospitals because sepsis has become a major public health problem as the leading cause of death of newborns worldwide. We need more studies related to this area as well as the work of a multidisciplinary body that would both improve and specialise treatment.
